Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...
AstraZeneca has been hit with a US class action lawsuit that claims the UK’s largest listed company misled shareholders in connection with investigations by Chinese authorities.
Indicates growing incidence of cancer among Indian population; five out of top 20 new brand launches are cancer drugs ...
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer ...
By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.
The approach requires balance, however. There is the risk of increased AEs, as well as financial toxicity. Friedlander shared ...
AstraZeneca Plc reported better-than-expected profit and revenue in the fourth quarter and forecast further gains, helped by ...
India's pharma market has introduced 3,151 new brands in the past year, with AstraZeneca's cancer drug Enhertu becoming the ...
India's pharmaceutical market is witnessing a surge in new drug launches, particularly in the oncology segment, fueled by a ...
Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...
Market OverviewThe Global Breast Cancer Therapeutics Market remains one of the most prevalent forms of cancer worldwide, ...
AstraZeneca on Thursday said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, raising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results